Evaluation of the efficacy of micronized natural progesterone (Seidigestan®) vs GnRH antagonists (Astarté®) in the prevention of LH surge during controlled ovarian stimulation: a randomized clinical trial.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504188-18-00

Acronym

IBMR43

Enrollment

150

Registered

2023-05-09

Start date

2023-11-08

Completion date

Unknown

Last updated

2023-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women undergoing ovarian stimulation for oocyte donation.

Brief summary

Number of oocytes obtained at metaphase II (MII) stage.

Detailed description

Number of cumulus-oocyte complexes (CCO) obtained., Number of germinal vesicles (VG)., Number of metaphase I (MI)., Number of oocytes suitable for insemination or microinjection.

Interventions

DRUGBemfola 150 IU/0.25 mL solution for injection in pre-filled pen

DRUGDecapeptyl diario 0

DRUG1 mg polvo y disolvente para solución inyectable

DRUGBemfola 225 IU/0.375 mL solution for injection in pre-filled pen

DRUGOvaleap 300 IU/0.5 mL solution for injection

DRUGAstarté 0

DRUG25 mg/0

DRUG5 ml solución inyectable en jeringa precargada EFG

DRUGSeidigestan 200 mg cápsulas blandas

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of oocytes obtained at metaphase II (MII) stage.	—

Secondary

Measure	Time frame
Number of cumulus-oocyte complexes (CCO) obtained., Number of germinal vesicles (VG)., Number of metaphase I (MI)., Number of oocytes suitable for insemination or microinjection.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026